Management of small-cell lung cancer in the elderly

Critical Reviews in Oncology/Hematology

Volumn 41, Issue 1, 2002, Pages 79-88

  Gridelli, C ^a   De Vivo, R ^b   Monfardini, S ^c  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SAN BORTOLO HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Chemotherapy; Elderly; G STEP; SCLC

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; TENIPOSIDE;

AGE; AGED; BLOOD TOXICITY; BONE MARROW TOXICITY; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DRUG TOLERABILITY; HUMAN; LUNG SMALL CELL CANCER; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW;

AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; PALLIATIVE CARE;

EID: 0036142363     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00163-9     Document Type: Review

References (91)

1. Cancer statistics
2. Lung cancer in the elderly
3. The National Cancer Institute on Aging and the National Cancer Institute SEER. Collaborative study on comorbidity and early diagnosis of cancer in the elderly
4. Treatment of small cell lung cancer patients
5. Staging systems of lung cancer
6. Chemotherapy of lung cancer
7. Treatment of the elderly patients with small-cell lung cancer
8. Treatment of small cell lung cancer in the elderly
9. Treatment of small cell lung cancer in the elderly
10. Geriatric pharmacology: basic and clinical considerations
11. Pharmacology of chemotherapy in the older cancer patients
12. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function
13. Age-related declines in hematopoietic reserve capacity
14. Cancer treatment protocols: who gets chosen
15. Choice of cancer therapy varies with age of patient
16. Social economic factors in the choice of lung cancer treatment. A population-based study in two rural states
17. Under-representation of patients 65 years of age or older in cancer-treatment trials
18. Cancer in the elderly: why so badly treated
19. Aging and cancer: issues of basic and clinical science
20. Comprehensive health screening of well elderly adults
21. Validation of a multidimensional evaluation scale for use in elderly cancer patients
22. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation
23. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale
24. Studies of illness in the aged: the index of ADL - A standardized measure of biological and psychosocial function
25. Scales to measure competence in everyday activities
26. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version in TL
27. Mini Mental State': a practical method for grading the cognitive status of patients for the clinician
28. Mini-Mental state examination: a normative study in Italian elderly population
29. Mini Nutritional Assessment: a practical assessment tool for grading the nutritional state of elderly patients
30. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study
31. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study
32. Importance of functional measures in predicting mortality among older hospitalized patients
33. Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group study
34. Increased mortality rates in late-life depression
35. Depression and mortality in medically ill older adults
36. Malnutrition is an adverse prognostic factor in the outcome of treatment of patients with standard-risk acute lymphoblastic leukaemia
37. Comorbidity and functional status are independent in older cancer patients
38. Commission of the European Communities 'Europe Against Cancer Programme'. European School of Oncology advisory report. Cancer treatment in the elderly
39. Instruments for the functional assessment of older patients
40. Cancer treatment and age: patient perspectives
41. Chemotherapy of metastatic breast cancer in the elderly: the Piedmont Oncology Association experience
42. Should age be a determinant factor in treating breast cancer patients with combination chemotherapy?
43. Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: an Illinois Cancer Center study
44. Cyclophosphamide, methotrexate and 5-fluorouracil chemotherapy in women more than 65 year old with advanced breast cancer: the elimination of age trend in toxicity by using doses based on creatinine clearance
45. Evidence-based management of cancer in the elderly
46. Physiology of aging: relevance to symptoms, perceptions and treatment tolerance
47. Age and sex are independent predictors of 5-fluorouracil toxicity: analysis of a large scale phase III trial
48. Small cell carcinoma of the lung: derivation of a prognostic staging system
49. Small cell carcinoma of the lung: influence of age on treatment outcome
50. Treatment of small cell lung carcinoma in the elderly
51. Influence of age on the treatment of limited-stage small-cell lung cancer
52. Full chemotherapy in elderly patients with small cell bronchial carcinoma
53. Treatment of small cell lung cancer (SCLC) in elderly patients
54. Similar outcome of elderly patients in intergroup trial 0096: cisplatin (P), etoposide (E), and thoracic radiotherapy (TRT) administered once (QD) or twice daily (BID) in limited stage small cell lung cancer (SCLC)
55. Retrospective review of chemotherapy for small cell lung cancer in the elderly: does the end justify the means?
56. Chemotherapy in elderly patients with small cell lung cancer
57. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer
58. Single-agent oral etoposide for elderly small cell lung cancer patients
59. Single agent oral etoposide in advanced NSCLC (chronic daily) and in elderly patients with SCLC
60. A phase II study of oral etoposide in elderly patients with small cell lung cancer
61. A phase II study of oral etoposide 100 mg/day for 21 days Q5 weeks in untreated elderly and poor performance status small cell lung cancer patients
62. Oral etoposide (VP-16) every 3 wks or continously to elderly patients with small cell lung cancer (SCLC): preliminary results of a randomised study
63. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party
64. 4-Epidoxorubicin in elderly or unfit patients with small cell lung cancer: a phase II experience by the EORTC Lung Cancer Cooperative Group
65. Teniposide as single drug therapy for elderly patients affected by small cell lung cancer
66. The clinical impact of teniposide in the treatment of elderly patients with small cell lung cancer
67. Oral etoposide and carboplatin. Effective therapy for elderly patients with small cell lung cancer
68. Phase II trial of carboplatin plus oral etoposide for elderly patients with small cell lung cancer
69. Carboplatin, etoposide and accelerated hyperfractionated radiotherapy for elderly patients with limited small lung carcinoma
70. Carboplatin and etoposide for small cell lung cancer in patients aged 70 years or over: impact of carboplatin dose on treatment results
71. Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small cell lung cancer
72. Carboplatin-etoposide in elderly small cell lung cancer patients: a phase II study
73. Tolerability of a combination of carboplatin and etoposide phosphate in elderly patients with small cell lung cancer. A multicentric phase II clinical trial
74. A novel regimen for the treatment of small cell lung cancer (SCLC) in the elderly
75. Weekly carboplatin and VM-26 for elderly patients with small cell lung cancer
76. New combination of the old drugs for elderly patients with small cell lung cancer. A phase II study of the PAVE regimen
77. Full dose chemotherapy plus lenograstim and low dose CT in elderly SCLC patients A phase II randomised FONICAP-GSTPV study
78. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC)
79. A meta-analysis of thoracic radiotherapy for small-cell lung cancer
80. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin and vincristine
81. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission
82. Age has no impact on acute and late toxicity of curative thoracic radiotherapy
83. Abbreviated treatment for elderly, infirm or noncompliant patients with limited-stage small-cell lung cancer
84. Carboplatin, etoposide and accelerated hyperfractionated radiotherapy for elderly patients with limited small lung carcinoma
85. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation induced encephalopathy